PATRICK J. LOEHRER, M.D.; LAWRENCE H. EINHORN, M.D.
Cisplatin is a metal coordination compound that was approved for clinical use in treating testicular cancer 5 years ago. Although early trials showed marked gastrointestinal and renal toxicities, treatment-related morbidity has been significantly alleviated with modern antiemetic therapy and adequate pretreatment hydration. More recent clinical studies of cisplatin have shown a broad range of activity and provide a better understanding of the drug's pharmacology, mechanism of action, and toxicity. Variations in the dosage and mode of administration as well as development of cisplatin analogues are being currently studied.
LOEHRER PJ, EINHORN LH. Cisplatin. Ann Intern Med. 1984;100:704–713. doi: 10.7326/0003-4819-100-5-704
Download citation file:
Published: Ann Intern Med. 1984;100(5):704-713.
Emergency Medicine, Hematology/Oncology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use